Full Press Release Details
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
Please find enclosed a Press Release on "Dr.
Reddy's launches in-house palbociclib (PRIMCYV ) to widen access to high-quality breast cancer drug."
This is for your information.
For Dr. Reddy's Laboratories Limited
| /s/ K Randhir Singh | |
| K Randhir Singh | |
| Company Secretary, Compliance Officer and Head-CSR |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, India. | Richa Periwal richaperiwal@drreddys.com | USHA IYER ushaiyer@drreddys.com |
launches in-house palbociclib (PRIMCYV ) to
to high-quality breast cancer drug
Hyderabad, India; January 13, 2023 -
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as "Dr. Reddy's"),
announced that it has acquired the trademark rights of the breast cancer drug PRIMCYV from Pfizer Products India Pvt Ltd for use
in the Indian market.
PRIMCYV is a targeted therapy containing
the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line
treatment of adult patients with HR+, HER2- metastatic breast cancer. Since May 2022, Dr. Reddy's has been marketing the drug in
collaboration with Pfizer Products India Pvt Ltd under the brand name PRIMCYV in India. The drug comes in the form of hard capsules
in strengths of 75 mg, 100 mg and 125 mg.
Following the trademark rights acquisition, Dr.
Reddy's will manufacture the Active Pharmaceutical Ingredient (API) and finished drug at its state-of-the-art facilities approved
by the United States Food and Drug Administration (USFDA). Dr. Reddy's is amongst select companies in the world to have conducted
a bioequivalence study and received tentative approval from the USFDA for palbociclib. The in-house product will be retailed in the Indian
market at a reduction of 85% from the current MRP to increase affordability and access to palbociclib. Dr. Reddy's plans to roll
out a unique Patient Assistance Programme to support long-term therapy of the patients on PRIMCYV .
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, India. | Richa Periwal richaperiwal@drreddys.com | USHA IYER ushaiyer@drreddys.com |
Through leading brands such as Hervycta, Mitotax,
Docetere, Nab Mitotax, PRIMCYV and others, Dr. Reddy's has made a portfolio of reliable and high-quality medicines available to
patients in India in keeping with its purpose of Good Health Can't Wait'.
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad,
India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Good
Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars
and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep
science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter
of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high
in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions and
involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general
economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels
and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition
and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the
impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets
addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics
or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings
with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"
sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information